Protocolo diagnóstico y terapéutico de la hipercalcemia en el enfermo oncológico
- Herrero Fernández, M.
- Villalba Yllán, A.
- Molina Villaverde, R.
- Álvarez-Mon Soto, M.
ISSN: 0304-5412
Année de publication: 2017
Titre de la publication: Enfermedades oncológicas (III) Tumores genitourinarios. Melanoma
Serie: 12
Número: 33
Pages: 2000-2004
Type: Article
D'autres publications dans: Medicine: Programa de Formación Médica Continuada Acreditado
Résumé
Abstract Introduction Hypercalcaemia is the most common metabolic emergency in cancer. Epidemiology It affects 10%-20% of patients and is most common in cancers of the lung, breast, prostate, and multiple myeloma. Definition Hypercalcaemia is considered to be a total plasma calcium level of above 10.5 mg/dl. Symptoms Initial symptoms are usually asthaenia, lethargy and constipation and subsequently vomiting and polyuria, which can result in major dehydration and trigger stupor or coma. Treatment Treatment is currently based on hydration and bisphosphonates.
Références bibliographiques
- Lumachi F, Brunello A, Roma A, Basso U. Cancer induced hypercalcemia. Anticancer Res. 2009;29(5):1551-5.
- Goldner W. Cancer-related hypercalcemia. J Oncol Pract Am Soc Clin Oncol. 2016;12(5):426-32.
- Stewart AF. Clinical practice. Hypercalcemia associated with cancer. N Engl J Med. 2005;352(4):373-9.
- Clines GA, Guise TA. Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone. Endocr Relat Cancer. 2005;12(3):549-83.
- Mirrakhimov AE. Hypercalcemia of malignancy: an update on pathogenesis and management. North Am J Med Sci. 2015;7(11):483-93.
- Legrand SB. Modern management of malignant hypercalcemia. Am J Hosp Palliat Care. 2011;28(7):515-7.
- Dietzek A, Connelly K, Cotugno M, Bartel S, McDonnell AM. Denosumab in hypercalcemia of malignancy: a case series. J Oncol Pharm Pract Off Publ Int Soc Oncol Pharm Pract. 2015;21(2):143-7.
- Hu MI, Glezerman IG, Leboulleux S, Insogna K, Gucalp R, Misiorowski W. Denosumab for treatment of hypercalcemia of malignancy. J Clin Endocrinol Metab. 2014;99(9):3144-52.